PIK3CA and breast carcinoma: As the PI3K/Akt/mTOR pathway is heavily deregulated in breast cancer [8,9], inhibitors of mTOR are of interest as potential therapeutic agents for breast cancer patients, with everolimus and temsirolimus being the key drugs considered (S1 Table).